Accepted Manuscript

Title: Peripheral modulation of the endocannabinoid system in metabolic disease

Authors: Nirajan Shrestha, James S.M. Cuffe, Dana S. Hutchinson, John P. Headrick, Anthony V. Perkins, Andrew J. McAinch, Deanne H. Hryciw

PII: S1359-6446(17)30415-4
DOI: https://doi.org/10.1016/j.drudis.2018.01.029
Reference: DRUDIS 2162

To appear in:

Please cite this article as: Shrestha, Nirajan, Cuffe, James S.M., Hutchinson, Dana S., Headrick, John P., Perkins, Anthony V., McAinch, Andrew J., Hryciw, Deanne H., Peripheral modulation of the endocannabinoid system in metabolic disease.Drug Discovery Today https://doi.org/10.1016/j.drudis.2018.01.029

Peripheral modulation of the endocannabinoid system in metabolic disease

Nirajan Shrestha[1], James S.M. Cuffe[1], Dana S. Hutchinson[2], John P. Headrick[1], Anthony V. Perkins[1], Andrew J. McAinch[3,4] and Deanne H. Hryciw[3,5,*]

[1]School of Medical Science, Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD, Australia

[2]Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia

[3]Centre for Chronic Disease, College of Health and Biomedicine, Victoria University, Melbourne, VIC, Australia

[4]Australian Institute of Musculoskeletal Science (AIMSS), College of Health and Biomedicine, Victoria University, Melbourne, VIC, Australia

[5]School of Natural Science, Menzies Health Institute Queensland, Griffith University, Nathan, QLD, Australia

[*]*Corresponding author*: Hryciw, D.H. (d.skelly@griffith.edu.au).

Highlights:

- The endocannabinoid system (ECS) is dysregulated in obesity-associated diseases
- CB_1 antagonism is a potential therapeutic target for the treatment of obesity
- CB_1 antagonists have the potential for eliciting severe psychiatric side effects
- Antagonists of CB_1 that do not cross the blood–brain barrier are in development
- Peripherally restricted CB_1 antagonists are novel therapeutic targets for obesity

Teaser: This Keynote review discusses the peripheral modulation of the ECS in liver, adipose tissue, heart, skeletal muscle, gastrointestinal tract, pancreas, kidney and the immuno-inflammatory system.